Icon

ARRANON (nda021877)- (250MG/50ML (5MG/ML))

NELARABINE SANDOZ
250MG/50ML (5MG/ML)
No No
2017-Jun-13 Expired
None None
None No
ARRANON is indicated for the treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.
7 0 6
Total Other Developers 12
Drugs with Suitability No
250MG/50ML (5MG/ML) ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 4
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ***** ****** ***** ************ ******* *********** **** **. **, ******* ******* ******** ****, ******* - ***** *. *. **. **, ******, *** : ******, *********, ******* ******, ***** (***) ***
****** ** ****** **.*****'* ************ ******* *********** ** ** ** & ** ** **, ***** - ***, ****, *******,, *************, ****** ******* *** ***, ***** (***) ***
****** ****** ****** *************** **., ***. *********** **.*-* ***** ****, ******* **-**** ************* ****** ****, *******, ******* ******, ***** (***) ***
****** ****** ****** **** *********** *******. **, ******, *****, ******* (***) ***
****** ****** ****** ******** ******* ******* *********** **** **. *-*, *-*, *-**, *****-*** *******-********* ******-********* *************, *************, ** ******, ***** (***) ***
****** ***** ****** *** ***** ****** ******* *********** **** * & **** **, ***** *, ***** *, ************* ******* ******** **** (**** ), *******, *************, ****** ******* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.